Is CareDx, Inc (CDNA) a Buy, Sell, or Hold?
NASDAQ : CDNA
CareDx, Inc
$38.8 USD
-$0.93 (-2.34%)
- Volume
- 871.78K
- Average Volume
- 878.43K
- Market Capitalization
- $2B
- P/E Ratio
- -245.41
- Dividend Yield
- 0.00%
- Price Target
- $40.00
- Year High
- $40.47
- Year Low
- $11.26
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.40
Company Overview
NASDAQ
John Walter Hanna Jr.
Medical - Diagnostics & Research
Healthcare
CDNA
765
US
USD
Liquidity Metrics
0.08
3.40
3.07
0.98
0.00
Sales & Valuation
$379.8M
4.86
6.33
30.75
1.27
Profitability
-$0.4
-$21.35M
-1.98%
-1.94%
-2.61%
-1.99%
P/E Metrics
-245.41
1.60
1.60
Analyst Price Target & Rating
$40.00
$45.00
$35.00
2/5
13 Analysts
-3.00%
Company Executives
| Name | Title |
|---|---|
| Jeffrey A. Novack | General Counsel & Secretary |
| Marica Grskovic | Chief Strategy Officer |
| John Walter Hanna Jr. | President, Chief Executive Officer & Director |
| Jessica Meng | Chief Commercial Officer |
| Kashif Rathore | Chief Technology Officer |
| Keith S. Kennedy | CFO & COO |
| Natasha Moshirian Wagner | Vice President of Corporate Communications |
| Jing Huang | Chief Data & Artificial Intelligence Officer |
| Tina Jacobsen | Vice President of Investor Relations |
| Robert N. Woodward | Chief Scientific Officer |
Poll Results
No votes yet today — be the first to share your view!
About CareDx, Inc (NASDAQ:CDNA) Stock
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSig ... ht HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
CareDx's Growth Prospects With Naveris Keep Me Bullish
2026-07-20 08:15:00
CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into transplant centers. I also think CDNA's AlloHeme gives them longer-term optionality in post-cell-therapy monitoring. More recently, CDNA sold Lab Products and purchased Naveris. These major strategic M&A deals mean CDNA now has a potential growth engine in oncology.
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?
2026-07-17 06:20:19
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
2026-07-16 08:35:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of Car.
2026-07-16 08:30:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx's transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for sur.
CareDx Completes Naveris Acquisition and Expands Oncology Reach
2026-07-07 12:26:07
CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder
2026-07-07 08:01:24
CareDx has transformed into a focused, high-acuity specialty diagnostics platform, emphasizing repeat testing, data-rich services, and workflow integration. Recent strategic actions—Lab Products divestiture, Naveris acquisition, and VANTx launch—sharpen CDNA's growth profile, recurring revenue, and margin potential. Q1 2026 marked a shift to operating leverage: 39% revenue growth, gross margin expansion to 71%, and positive net income, with strong guidance for 2026.
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
2026-07-01 16:05:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — in.
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
2026-06-30 16:05:00
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearan.
Frequently Asked Questions
-
What is the current CareDx, Inc (CDNA) stock price?
-
CareDx, Inc(NASDAQ:CDNA) stock price is $38.8 in the last trading session. During the trading session, CDNA stock reached the peak price of $40.47 while $11.259 was the lowest point it dropped to. The percentage change in CDNA stock occurred in the recent session was --2.34% while the dollar amount for the price change in CDNA stock was -$0.93.
-
CDNA's industry and sector of operation?
-
The NASDAQ listed CDNA is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of CDNA?
-
Jeffrey A. Novack | General Counsel & Secretary
Marica Grskovic | Chief Strategy Officer
John Walter Hanna Jr. | President, Chief Executive Officer & Director
Jessica Meng | Chief Commercial Officer
Kashif Rathore | Chief Technology Officer -
How many employees does CDNA have?
-
Number of CDNA employees currently stands at 765. CDNA operates from 8000 Marina Boulevard, Brisbane, CA 94080, US.
-
Link for CDNA official website?
-
Official Website of CDNA is: https://www.caredx.com
-
How do I contact CDNA?
-
CDNA could be contacted at phone #415 287 2300 and can also be accessed through its website. CDNA operates from 8000 Marina Boulevard, Brisbane, CA 94080, US.
-
How many shares of CDNA are traded daily?
-
The average number of CDNA shares traded daily for last 3 months was 878.43K.
-
What is the market cap of CDNA currently?
-
The market value of CDNA currently stands at $2B with its latest stock price at $38.8